Nature communications
Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants.
Min Wang, Jinyue Yang, Yahong Tan, Shuofeng Yuan, Guoli Shi, Qi Peng, Yongqi Li, Vincent Kwok-Man Poon, Chris Chung-Sing Chan, Na Xiao, Anna Jinxia Zhang, Yubin Xie, Junhua Li, Hao Luo, Yaning Fu
Published: 202610.1038/s41467-026-68462-9
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to cause significant morbidity and mortality despite the end of its pandemic phase. The emergence of highly mutated SARS-CoV-2 variants of concern highlights the requirement of br…
Preview only. Read the full abstract at the source